Mereo BioPharma Group plc Overview
Pro stress-test →Mereo BioPharma is a biopharmaceutical company developing therapeutics for oncology and rare diseases. Founded in 2015, Mereo was established to fund and develop high-potential novel therapies that were not being progressed in pharma or biotech companies for strategic reasons. The company faces critical near-term challenges following recent setbacks in its lead programs.
Strategic Profile
Pro stress-test →Mereo identifies and develops de-prioritized, de-risked assets from pharma partners through deep ecosystem relationships and flexible, capital-efficient execution. Its two primary rare disease candidates are setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. However, both Phase 3 ORBIT and COSMIC programs failed to achieve endpoints against placebo or control groups, triggering ongoing securities litigation.
Competitive Landscape
Pro stress-test →Mereo competes in the rare disease biotech space with companies like Ultragenyx Pharmaceutical, Zenas BioPharma, and Outlook Therapeutics. Unlike larger peers with diversified pipelines, Mereo's model is highly dependent on few lead assets. The Phase 3 failures have significantly weakened competitive positioning relative to peers developing similar assets.
Industry Context
Mereo BioPharma Group plc operates in Biopharmaceutical - Clinical Stage / Rare Diseases.
Key facts
Founded: 2015 · Headquarters: London, UK